News & Updates
Filter by Specialty:
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
Patients with type 2 diabetes mellitus (T2DM) taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) are less likely to be prescribed antigout or antihyperuricaemic drugs, a recent study has found.
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
28 Aug 2022Dulaglutide safely controls glucose in T2D with CKD
In patients with type 2 diabetes (T2D) with chronic kidney disease (CKD), once-weekly dosage with dulaglutide achieves adequate glycaemic control along with a reduced decline in estimated glomerular filtration rate (eGFR), reports a recent study.
Dulaglutide safely controls glucose in T2D with CKD
28 Aug 2022Early transition to oral antimicrobials prevents treatment failure in children with SAB, AHO
Children with Staphylococcus aureus bacteraemia (SAB), a common complication of acute hematogenous osteomyelitis (AHO), are vulnerable to a wide range of illnesses, suggests a study. Thus, classifying its severity may aid in treatment decision-making.
Early transition to oral antimicrobials prevents treatment failure in children with SAB, AHO
27 Aug 2022Adjuvant sorafenib after RFA boosts survival in recurrent hepatocellular carcinoma
The use of sorafenib as an adjuvant therapy after radiofrequency ablation (RFA) appears to improve survival outcomes in patients with recurrent hepatocellular carcinoma who underwent hepatectomy, according to a study.
Adjuvant sorafenib after RFA boosts survival in recurrent hepatocellular carcinoma
27 Aug 2022Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
Use of pimavanserin appears to be more effective than atypical antipsychotic agents in reducing mortality among Parkinson’s disease patients during the first 180 days of treatment, reveals a study. However, such benefit is seen only in community-dwelling patients and not in nursing home residents.
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
26 Aug 2022Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.